The influence of plasma binding on absorption/exsorption in the Caco-2 model of human intestinal absorption.
The Caco-2 cell monolayer has become an increasingly useful in-vitro model of human intestinal absorption. In this study we have determined the effect of plasma on the basolateral side on the absorption as well as exsorption of several drugs that are highly bound to plasma proteins. The drugs used included propranolol and quercetin, which both use the transcellular route of absorption, and taxol and oestradiol 17 beta-D-glucuronide, which are thought to undergo efflux by P-glycoprotein and the multidrug resistance protein MRP, respectively. All experiments were carried out under sink conditions to mimic normal absorption. It was necessary to use heparin anticoagulation for generation of the plasma, as EDTA was found to make the monolayers very leaky. The apparent permeability (P(app)) values for absorption were 1.54 x 10(-6) cm s(-1) for oestradiol 17 beta-D-glucuronide, 3.33 x 10(-6) cm s(-1) for taxol, 20.8 x 10(-6) cm s (-1) for quercetin, and 35.3 x 10(-6) cm s(-1) for propranolol. For these four compounds, plasma on the basolateral side had no influence on absorption. However, plasma on the basolateral side significantly reduced the efflux of oestradiol 17 beta-D-glucuronide by 66%, taxol by 75%, propranolol by 82%, and quercetin by 94%. Failure to consider the effect of plasma binding can result in an overestimate of basolateral to apical efflux and result in misleading net flux calculations.
Walgren
R A
RA
Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston 29425, USA.
Walle
T
T
D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics*; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics*; D001692:Biological Transport; D001798:Blood Proteins / Q000378:metabolism*; D018938:Caco-2 Cells / Q000378:metabolism*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D006801:Humans; D007408:Intestinal Absorption; D008954:Models, Biological; D017239:Paclitaxel / Q000493:pharmacokinetics*; D011433:Propranolol / Q000493:pharmacokinetics*; D011794:Quercetin / Q000493:pharmacokinetics
D000319:Adrenergic beta-Antagonists; D000972:Antineoplastic Agents, Phytogenic; D001798:Blood Proteins; C025483:estradiol-17 beta-glucuronide; D004958:Estradiol; D011794:Quercetin; D011433:Propranolol; D017239:Paclitaxel